Project Grant R01HL183230
Award Date 8/24/26
Completion Date 5/31/30
Dollars Obligated $740K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $222,750 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how innate lymphoid cell memory formed during neonatal lung injury contributes to chronic obstructive pulmonary disease development in adulthood. The project, titled "Trained Immunity in Group 2 Innate Lymphoid Cells Links Neonatal to Adult Chronic Lung...
- The National Heart, Lung, and Blood Institute awarded $207,488 to the Regents of the University of Michigan on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research into the role of tryptophan metabolism in idiopathic pulmonary fibrosis. The research investigates how tryptophan metabolites, particularly those produced through the kynurenine pathway, activate immune signaling mechanisms that contribute to pulmonary fibrosis progression. The...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $678,379 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study the cellular biology and function of pulmonary ionocytes. The research investigates pulmonary ionocytes, rare epithelial cells in surface airway epithelium and submucosal glands that highly express the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ionocytes regulate airway surface...
- The National Heart, Lung, and Blood Institute awarded Boston University a Project Grant of $1,605,354 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung interstitial macrophages and their role in bacterial pneumonia defense. The research examines two major subsets of lung interstitial macrophages—CD206+ and CD206—that occupy distinct anatomic niches and perform different immune functions. Preliminary findings indicate that both subsets...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $354,982 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune mechanisms driving lung fibrosis following severe viral respiratory infections. The research dissects how aberrant immune-epithelial interactions perpetuate post-viral lung damage distinct from idiopathic pulmonary fibrosis. The work focuses on three objectives: defining mechanisms that sustain...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart Lung and Blood Institute awarded Northwestern University $104,928 for a Project Grant (K99HL188111) on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research targeting lipid signaling pathways in perivascular interstitial macrophages as a therapeutic strategy for pulmonary fibrosis. The investigator will use single-cell spatial transcriptomics and RNA sequencing to characterize how perivascular interstitial macrophages...
- The National Heart, Lung, and Blood Institute awarded Cincinnati Children's Hospital Medical Center $249,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 2, 2026, to support research on the role of subpleural fibroblasts in pulmonary fibrosis progression. The funded research investigates idiopathic pulmonary fibrosis (IPF), which begins with scar tissue buildup at the lung edges and advances centrally. The project applies lineage tracing, mouse modeling, and...